WALL – The Philippines Food and Drug Administration (FDA) announced that Coronavac, the corona virus vaccine developed by the Chinese company Sinovac, was given urgent use approval, but healthcare professionals would not be made from this vaccine due to ‘inconsistency in efficacy levels’. FDA President Rolando Enrique Domingo said the effectiveness rate of Coronavac in healthcare workers exposed to Covid-19 was lower compared to healthy individuals aged 18-59. “According to our experts, the Sinovac vaccine is not the best vaccine for them,” Domingo said.
Coronavac Brazil, Turkey and Indonesia pointing to experiments conducted in the official, the risk of exposure to Covidien-19 infection reported whether the administration of the vaccine to high health care workers. The Beijing administration announced in January that 600,000 doses of Coronavac vaccine would be donated to the Philippines, which has not yet started its mass vaccination program.
Sinovac’t In a statement, Turkey also uses 100 percent in preventing severe cases of vaccine Coronavac, while just over 50 percent in the prevention of mild cases was described as successful. In January, the results of the studies conducted in Brazil were announced, and the Bhutantan Institute stated that the ‘general protection rate’ of the vaccine in the trials in the country was 50.38 percent.
For the vaccine developed by Sinovac, it was announced that 65 percent protection rate was provided in the experiments conducted in Indonesia and the vaccine was given urgent approval. Turkey announced that the Phase 3 trial of intermediate results in a rate of 91.25 percent protection measured. Unlike Turkey and Indonesia, he had participated in the trial volunteers over 60 years in Brazil. (EXTERNAL NEWS)
#Coronavac #leave #healthcare #workers #Philippines #effectiveness #rates #inconsistent